Physician profile
Ho Bae
NPI 1053337998
$24,311.80
in general payments reported to CMS, 2019-2025
14 companies · $3,478 in 2025
The $3,478 reported for 2025 was more than what 88% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $4,685 · 2021: $119 · 2022: $237 · 2023: $167 · 2024: $136 · 2025: $3,478.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,200 · Food and Beverage: $581.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,200.00 |
| Food and Beverage | $580.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $20,212.94 | 2019-2025 | |
| Glaxosmithkline, LLC. | $3,200.00 | 2025 | |
| Amgen INC. | $358.23 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $125.00 | 2019 | |
| Ardelyx, INC. | $96.47 | 2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $93.51 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $69.64 | 2025 | Voquezna |
| Celgene Corporation | $41.78 | 2024 | Zeposia |
| Abbvie INC. | $40.11 | 2023-2024 | Mavyret |
| Alnylam Pharmaceuticals INC. | $26.24 | 2022 | |
| Allergan, INC. | $16.56 | 2019 | |
| Ironwood Pharmaceuticals, INC | $16.32 | 2023 | Linzess |
| Boston Scientific Corporation | $15.00 | 2023 | Lux-Dx Insertable Cardiac Monitor |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ho Bae listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.